BIOHIT OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.02 EUR | +2.02% |
|
+1.00% | +7.16% |
| 14/06 | Finland's Biohit Names Chief Technology Officer | MT |
| 15/04 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 47% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
Ratings chart - Surperformance
Sector: Office Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +7.16% | 32.81M | - | ||
| +2.11% | 7.36B | B- | ||
| -11.65% | 4.33B | B | ||
| +0.56% | 3.15B | - | ||
| +17.42% | 2.22B | - | ||
| +15.93% | 1.07B | C+ | ||
| -38.92% | 928M | - | ||
| +7.84% | 936M | - | ||
| -56.62% | 684M | - | ||
| -29.11% | 629M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIOBV Stock
- Ratings Biohit Oyj
